Does Fetuin-A, RAGE, FGF-23 levels associated with cardiovascular risk or fibrosis score in patients with metabolic dysfunction-associated steatotic liver disease?

Authors:
Publisher website
Google Scholar
Abstract
Aims: Increasing evidence suggests that cardiovascular disease risk increases in metabolic dysfunction-associated steatotic liver disease (MASLD). Fetuin-A, reseptor for advanced glycation end-products (RAGE) and fibroblast growth factor 23 (FGF-23) are associated with insulin resistance (IR), inflammation, oxidative stress, and so predispose to coronary heart disease (CHD). We aimed to investigate the clinical utility of Fetuin-A, RAGE and FGF-23 in assessing CHD risk evaluated by Framingham risk score (FRS) in patients with MASLD.Methods: The study included 80 individuals aged 34-82 years who met the diagnostic criteria for MASLD, and a control group of 60 individuals with normal liver echogenicity on ultrasonography and FRS values less than 10% in cardiac risk assessment. Patients in the MASLD group were further divided into two subgroups: low cardiac risk (FRS

This publication has 40 references indexed in Scilit: